ABSTRACT
INTRODUCTION
In Otolaryngology and Audiology practices, Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL) is considered to be an otological emergency. ISSNHL is defined as a decline in hearing over a period of 72 h or less and affecting 3 or more frequencies by 30 dB or greater (American Hearing Research Foundation) . Approximately 5-20 persons in 100,000 populations of patients who suffer from ISSNHL consult an otolaryngologist yearly (Abdullah et al. 2006; Chau et al. 2010; Kuhn et al. 2011) .
Considering that there is no standard protocol or universally accepted way to treat patients with ISSNHL, various therapies and agents such as steroids (systemic and local intratympanic), plasma expander, antiviral agents, anticoagulants, vasodilators, diuretics, vitamins, hyperbaric oxygen therapy and topical insulin-like growth factor therapy have been proposed as therapeutic agents to treat sudden sensorineural hearing loss (Ferri et al. 2012; Rausch et al. 2011) .
Systemic glucocorticoid is the most commonly used treatment for ISSNHL, since most cases of ISSNHL are due to an infectious, inflammatory or autoimmune process. In such cases, ISSNHL is usually treated with prednisolone or dexamethasone where the recommended dosage varies from 1 to 10 milligrams per kilogram of body weight. Improvements in hearing after systemic corticosteroid therapies, occurs in 50% of patients. However, approximately 20% of patients showed no improvement at all (Battaglia et al. 2008; Kong et al. 2014; Wang et al. 2016) .
Use of intratympanic (IT) steroid was evident since year 1991. Over the past decades, IT corticosteroid treatment is beginning to be more accepted in the treatment of ISSNHL due to the low probability of systemic adverse events and also due to the potential delivery of high concentrations of corticosteroid into the inner ear (Arastou et al. 2013) . However, studies done on IT corticosteroid employed a wide variation in terms of the dosage. To the best of our knowledge, no study has been done with IT steroid dosage of more than 60 mg/mL concentration. Thus, in the current study, the highest concentration of steroid available is employed to evaluate the possible hearing improvement outcomes as well as its possible side effects.
In ISSNHL, tinnitus and vertigo is the most common associated symptoms with 72-84% of patients suffering from tinnitus (Bennet et al. 2005; Mazita et al. 2008; Wan et al. 2013 ) and 40% patients complain of dizziness, vertigo, disequilibrium, imbalance or Meniere's like vertigo. Two studies suggested that IT steroid is also a good modality option in treating ISSNHL patients with Meniere like vertigo and tinnitus (Deenadayal et al. 2016; Noell et al. 2003; Ruszymah et al. 2005) .
PATIENTS AND METHODS
This clinical descriptive study was approved by the KPJ University College (KPJUC) Ethical Committee (KPJUC/M.ORL/EC/2015/004). The study was carried out in the Otorhinolaryngology Clinic, KPJ Ampang Puteri Specialist Hospital from 1st of March 2015 to 30th June 2016. Universal sampling technique was used in this study and consents were taken from the patients prior to the onset of study. The patients' age ranged between 18 and 60 years old, with ISSNHL of more than 30 dB at three consecutive frequencies within 3 days with normal hearing in the contralateral ear. IT steroid injections were given in patients with recovery of less than 10 dB after a two week's treatment of systemic steroid.
After a complete history taking, clinical examinations, pure tone audiogram (PTA) and several laboratory investigations (full blood count, coagulation profile, serum glucose, antinuclear antigen and serology for syphilis) were done. Magnetic resonance imaging (MRI) examinations of brain and cerebellopontine angle was performed on all patients to rule out intracranial retrocochlear pathology.
SYSTEMIC CORTICOSTEROIDS THERAPY
All the ISSNHL patients were given a two-week course of systemic steroid therapy of intravenous dexamethasone for 1 week and continued with oral prednisolone of 10 mg/body weight in tapering dose for another 8 days. Esomeprazole, 40 mg BD for two weeks, was given to the patients with risks of developing gastritis.
PTA is repeated after completion of two-week systemic steroid and patients with less than 10 dB improvement in PTA, averaged at four tested frequencies (500, 1000, 2000 and 4000 Hz) were included in the IT methylprednisolone study.
INTRATYMPANIC METHYLPREDNISOLONE INJECTION
Examinations of ears done under microscope and the external ear canal were cleansed using normal saline and suction under microscope.
The patient was placed in supine position, with the head tilted 45 degrees to the healthy ear side. Local anaesthesia was administrated using 5% EMLA cream (1 g contains 25 mg of Lidocaine and 25 mg of prilocaine) pasted on the tympanic membrane and outer ear canal. A 3 cc syringe filled with methylprednisolone (62.5 mg/mL) attaches to a 25G spinal needle and around 0.3-0.5 mL of methylprednisolone was injected into middle ear cavity at the anterior inferior quadrant of the tympanic membrane. The patient then lied laterally on the healthy site for 30 min after the procedure and was instructed to avoid yawning, coughing and speaking for 30 min. The procedure was repeated weekly for 3 weeks.
An improvement of 20 dB or the hearing thresholds below 20 dB (normal hearing) in the PTA average at 0.5, 1.0, 2 and 4 kHz was considered as an improvement in hearing.
STATISTICAL ANALYSIS IBM SPSS statistics version 23 and Microsoft Excel was used for data analysis. The comparison of mean PTA average before and after SCT and IT methylprednisolone therapy were assessed with Wilcoxon Signed Rank Test due to a smaller sample size. A p value ≤ 0.05 was considered significant. All the result are being expressed as mean +/-SEM.
RESULTS
Among the total of 4436 patients that visited the otorhinolaryngology outpatient clinic during our study period, 350 were with hearing problems and 36 (0.81%) were diagnosed with ISSNHL. There were 23 (63.9%) female and 13 (36.1%) male patients. The most common associated symptom in the patients was tinnitus which was seen in 28 out of 36 patients (77.8%), followed by vertigo in eight out of 36 (22.2%) patients. About 11.1% of patients had history of associated upper respiratory tract infection symptoms. There was only one patient (2.7%) who had associated history of otalgia.
A total of 32 patients completed the two weeks course of SCT. Eighteen patients (56.3%) had improvement of more than 10 dB in PTA average measurement posttreatment. Fourteen (43.7%) patients had no improvement or an average improvement in PTA of less than 10 dB. Two patients refused IT injections.
Twelve patients were recruited for IT methylprednisolone therapy. All the 12 patients received weekly IT injections for three weeks.
One month after completion of IT therapy, six of twelve patients showed more than 10 dB improvement in the PTA test with a median of 19.37 dB (p<0.05). Two patients had more than 20 dB hearing improvement.
The hearing outcome improved for all the mild, moderate and severe-profound hearing loss groups. Mild hearing loss group had a 10.9 dB improvement, moderate hearing loss improves by 19.07 dB and severe-profound improves by 14.69 dB (Figure 1 ).
All the hearing significantly improves after each IT injections (p<0.05). The most significant improvement is after the third IT therapy (p<0.005) ( Table 1) .
We included the hearing thresholds before and after IT injections in the four frequencies tested (500, 1000, 2000 and 4000 Hz). The lowest frequency (500 Hz) had the highest gain of 14 dB after IT therapy (p<0.05) followed by 4000 Hz at 11.67 dB gained (p<0.05), 2000 Hz at 7.22 dB (p<0.05) and 1000 Hz at 6.67 dB (p<0.05) ( Table 2) .
In this study, seven out of 12 patients had tinnitus and vertigo during the presentation. After IT methylprednisolone injections, only one patient suffered continuous tinnitus and vertigo while other improves significantly (Figure 2 ).
DISCUSSION
There were 32 patients who completed the two weeks treatment of systemic corticosteroids therapy. Out of these, 18 patients experienced hearing improvement of more than 10 dB with two regaining normal hearing and 14 patients showed no improvement at all. This was comparable with the previous studies done in which only 45-75% of patients regained normal hearing after SCT (Chandrasekhar 2003; Cinamon et al. 2001; Tucci et al. 2002) . Those who failed to have any significant improvement of more than 10 dB with SCT were included in our study and given weekly IT injection of methylprednisolone for 3 weeks duration.
I n t h e c u r r e n t s t u d y, h i g h e r d o s a g e o f methylprednisolone (62.5 mg/mL) was selected because higher concentration of steroid was proven to be more effective as it remained longer in the perilymph (Parnes et al. 1999) . Ho et al. (2004) later showed that weekly intervals of IT corticosteroids for three injections was proven to be better compared to the first two injections. In SCT and showed that ten of 14 (71.4%) patients had hearing recovery of more than 20 dB. However, none of the mentioned studies used a concentration of more than 40 mg/mL. The current study is the first report of the use of the highest concentration of IT steroid, 62.5 mg/mL, with no untoward side effect to the patients after the IT procedure. During one month follow up after the completion of IT therapy, six of 12 patients showed more than 10 dB improvement in the PTA with a median of 19.37 dB (p<0.05). Four patients had more than 20 dB hearing improvement. The improvements in other studies showed inconsistent results, with improvements range from 13 to 75% after IT injections, either as a sole procedure or in combination of systemic steroids (Arslan et al. 2011; Moon et al. 2011; Spear & Schwartz 2011) . This variation might be due to the difference in the concentration of steroid being used, or other factors such as the duration of first treatment and age. In our study, 50% of the patients did have improvement after 3 weeks IT procedure using high dose of methylprednisolone. This percentage, though even is on the higher range, does not prove to be of any advantage compared to the lower dosage of steroid done in previous studies. In addition, there was no significant side effect noted in all of our patients.
It is well known, factors such as delayed onset of treatment and presentation of severe to profound SSNHL, are signs of poor prognosis. In the current study, there were four patients presented with severe-profound sensorineural hearing loss on arrival with the mean PTA of 85.00 dB. After completion of the IT therapy, the mean PTA improved to 69.7 dB. None of these patients later regained normal hearing. However, none of them showed deteriorating mean PTA either. In fact, one of the patients are able to have improvement from profound to severe hearing loss with a PTA average gained of 16.25 dB. This is also comparable to other studies that showed improvement and more importantly the prevention of deterioration of hearing loss in severe SSNHL (Battaglia et al. 2008; Gundongan et al. 2013; Jong et al. 2010 ). This shows that IT procedure is important not only in gaining some recovery but also important in preventing further deterioration in severe to profound ISSNHL patients.
Tinnitus and vertigo are other symptoms associated with ISSNHL, which could be a frightening experience to the patients. Previous studies have shown that the symptom of tinnitus decreased from 70% to 30% after 7 to 10 days SCT. In IT steroid procedure the improvement is much higher, ranging from 75% to 100% (Choi et al. 2013; Hyun 2016; Mühlmeier et al. 2016 ). In the current study, in terms of tinnitus, there was a significant improvement in 7 out of 8 patients. The same goes with the symptom of vertigo, which have a higher range of improvement in SSNHL after IT procedure of nearly 100% (Alexander et al. 2015; Deenadayal et al. 2016b; She et al. 2009 ). In our study, the vertigo disappears in three out of 4 patients. 
CONCLUSION
The incidence of ISSNHL is rare and in our outpatient department accounts for 0.81%. Most of the patients presented to the ENT clinic quite early, with a mean of 4.8 days and all of them received treatment in less than two weeks.
There were 56.3% of patients with ISSNHL and their hearing improves after 2 weeks course of SCT. IT methylprednisolone procedure, significantly improves the hearing of 50% of the patients who previously not responding to SCT. However, these percentages are not different from other study that use lower concentration of steroid. The higher concentration does not have any short or long-term side effect. The procedure is also proven in improving the associated symptoms of tinnitus and vertigo.
